Compare Boston Scientific Corporation (BSX) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Eni SpA — how do they compare? Boston Scientific Corporation trades at $42.5 (market cap $66.37B), while Eni SpA trades at $49.17 (market cap $71.95B). The key difference: Boston Scientific Corporation and Eni SpA are close in size by market cap, and Eni SpA pays a 4.93% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | E | |
|---|---|---|
Market Cap | $66.37B | $71.95B |
Sector | Health | Energy |
52-Week High | $108.14 | $57.61 |
52-Week Low | $42.63 | $32.93 |
Enterprise Value | $75.94B | $90.86B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Eni (E) trades at $49.44, up 3.6% with a bullish technical signal supported by moving averages. The stock shows attractive valuation with P/E of 21.81 and P/S of 0.8, though revenue has declined from $132.5B in 2022 to $82.15B in 2025. Recent strategic moves include lithium investments in Chile, fusion energy partnerships, and global gas portfolio expansion. The company maintains positive cash flow with $238M net cash flow in 2025 and pays a $0.63 dividend.
Eni presents a mixed outlook with strong diversification efforts offset by declining revenue trends. The stock offers value characteristics with below-market valuations and dividend income, but faces headwinds from volatile energy markets and execution risks in new ventures. Analyst consensus leans cautious with 62% hold ratings, suggesting patience may be warranted despite current bullish technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
